Navigation path

Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information

Recombinant human CXCL8 mutant

EU orphan designation number: EU/3/13/1131   
Active ingredient: Recombinant human CXCL8 mutant
Indication: Treatment of cystic fibrosis
Sponsor: ProtAffin Biotechnologie AG
Impulszentrum Graz-West, Reininghausstrasse 13a, 8020 Graz, Österreich

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/06/2013 Orphan designation EMA/OD/005/13 (2013)3675 of 7/06/2013